Mahgoub MY, Elnady BM, Abdelkader HS, Abdelhalem RA, Hassan WA. Open Access Rheumatol. 2020;12: 55—63.
The authors have advised that Table 1 on pages 58 and 59 is incorrect. The correct table is shown below.
Table 1.
Baseline Characteristics of Different Groups
| Variable | KOA (n=59) Group I |
KOA Patients with FM (n=32 Group II |
FM (n=30) Group III |
P value | |
|---|---|---|---|---|---|
| Demographic | Age (years), mean ± SD | 53.4 ± 7.2 | 47.3 ± 4.6 | 37.5 ± 6.9 | <0.001* P1<0.001*, p2<0.001*, p3<0.001* |
| BMI, mean ± SD | 33.4 ± 3.1 | 33.3 ± 3.4 | 29.5 ± 3.9 | <0.001* p1<0.001*, p2<0.001*, p3=0.8 |
|
| Residence (rural: urban) | 34:25 | 22:10 | 18:12 | 0.58 | |
| Marital status (married: not married) | 49:10 | 23:9) | 19:11 | 0.11 | |
| Educational level (literate: illiterate) | 39:20 | 26:6 | 26:4 | 0.07 | |
| Clinical | Disease duration (years), median (IQR) | 3 (2-5) | 2 (1-3.5) | 2 (2-3) | 0.07 |
| KL grades, n (%) | |||||
| I | 16 (27.1) | 18 (56.3) | ---- | 0.02* | |
| II | 17 (28.8) | 7 (21.9) | ---- | ||
| III | 26 (44.1) | 7 (21.9) | ---- | ||
| VAS, median (IQR) | 3 (2.0-4.75) | 6 (5-8) | 5 (3-7) | <0.001* p1=0.002*, p2=0.04*, p3<0.001* |
|
| PSQI, mean ± SD | 7.5 ± 1.7 | 12.5 ± 2.5 | 9.1 ± 2.7 | <0.001* P1<0.001*, p2<0.001*, P3<0.001* |
|
| PASS20, mean ± SD | 35.9 ± 8.4 | 47.8 ± 10.9 | 40.5 ± 8.6 | <0.001* p1=0.02*, p2=0.005*, p3<0.001* |
|
| BDI-II, median (IQR) | 5 (2-7) | 14 (9-17.5) | 22.5 (18-27) | <0.001* p1<0.001*, p2<0.001*, p3<0.001* |
|
| Lequesene score, median (IQR) | 5 (4-7) | 7 (5.5-12) | ---- | <0.001* | |
| FIQ, mean ± SD | ---- | 49.5 ± 20.7 | 42.8 ± 13.2 | 0.14 | |
| Quality of life | Physical, mean ± SD | 49.8 ± 14.7 | 47.6 ± 14.1 | 62.1 ± 14.4 | <0.001* p1=<0.001*, p2=<0.001*, p3=0.5 |
| Cognitive, mean ± SD | 55.6 ± 15 | 49.9 ± 16.6 | 51.3 ± 14.8 | 0.2 | |
| Affective, mean ± SD | 53.5 ± 14.3 | 34.4 ± 17.3 | 47.6 ± 15.1 | <0.001* p1=0.07, p2=0.002*, p3<0.001* |
|
| Social, mean ± SD | 50.5 ± 15.2 | 45.8 ± 13.8 | 55.2 ± 12.4 | 0.04* P1=15, p2=0.006*, p3=0.14 |
|
| Economic, mean ± SD | 55.2 ± 19.1 | 54.8 ± 22.5 | 60.9 ± 16.5 | 0.36 | |
| Ego, mean ± SD | 47.8 ± 16 | 34.9 ± 15.9 | 35.9 ± 14.9 | <0.001* p1=0.001*, p2=0.8, p3<0.001* |
|
| Medications | Acetaminophen, n (%) | 49 (83) | 20 (62.5) | 15 (50) | 0.004* |
| NSAIDS, n (%) | 46 (78) | 27 (84.4) | 22 (73.3) | 0.6 | |
| Antidepressant, n (%) | 4 (6.8) | 12 (37.5) | 27 (90) | <0.001* | |
| Gabapentinoids, n (%) | 9 (15.3) | 16 (50) | 24 (80) | <0.001* | |
| Chondroprotctives, n (%) | 46 (78) | 21 (65.6) | 0 (0) | 0.3 |
Notes: P1: between KOA group and FM group; p2: between FM group and KOA patients with FM co-morbidity group; p3: between KOA group and KOA patients with FM co-morbidity group. *p<0.05.
Abbreviations: KOA, knee osteoarthritis; FM, fibromyalgia; BMI, body mass index; KL, Kellgren and Lawrence; VAS, visual analog scale; PSQI, Pittsburgh Sleep Quality Index; PASS20, Pain Anxiety Symptom Scale Short Form 20; BDI-II, Beck Depression Inventory; FIQ, Fibromyalgia Impact Questionnaire; NSAIDS, non-steroidal anti-inflammatory drugs.
The authors apologize for this error.